

March 12, 2026



Pelthos Therapeutics to Present at 38th Annual ROTH Conference

DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that CEO Scott Plesha will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026 at 3:00 p.m. Pacific Time.

Investors interested in arranging one-on-one meetings should contact their ROTH representative.

A live webcast of the fireside chat will be available on the News & Events page in the Investors section of the Company’s website at <https://pelthos.com>. A replay of the webcast will be available for 90 days following the event.

About Pelthos Therapeutics

Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI™ (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat *Molluscum contagiosum*. The company’s portfolio of assets also includes Xepi® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and Xeglyze® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on [LinkedIn](#) and [X](#).

Contacts

Investors:

LifeSci Advisors, LLC

Mike Moyer, Managing Director

mmoyer@lifesciadvisors.com

Media:

KWM Communications

Kellie Walsh

pelthos@kwmcommunications.com

(914) 315-6072



Source: Pelthos Therapeutics, Inc.